Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Poziotinib Shows Encouraging Activity Among Heavily Pretreated NSCLC Subgroup

September 25th 2018

Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.

Dr. Oxnard on Potential of Genome Wide Sequencing With cfDNA

September 25th 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the potential impact of implementing cell-free DNA tests as a method to detect signs of early stage cancer.

EU Panel Grants Positive Opinion to Brigatinib for ALK+ NSCLC

September 22nd 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended full approval of brigatinib (Alunbrig) as a treatment for patients with advanced ALK-positive non–small cell lung cancer who are previously treated with crizotinib (Xalkori).

Wakelee Highlights Latest Treatment Strategies in EGFR+ NSCLC

September 22nd 2018

Heather Wakelee, MD, shares insight on emerging treatment strategies in EGFR–positive non–small cell lung cancer.

Forde Focuses on Future of Early-Stage NSCLC

September 21st 2018

Patrick M. Forde, MBBCh, discusses the advances in early-stage non–small cell lung cancer, emphasizing neoadjuvant and adjuvant immunotherapy trials in stage I, II, and III disease.

Dr. Gentzler on Combination Therapies in NSCLC

September 21st 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Dr. Bunn on the Treatment of Early-Stage Lung Cancer

September 20th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the treatment of patients with early-stage non–small cell lung cancer.

Dr. Brahmer on Immunotherapy in Stage IV NSCLC

September 18th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses immunotherapy for patients with stage IV non–small cell lung cancer.

Targeted Therapies Continue to Show Potential for Less Common Drivers in NSCLC

September 18th 2018

Josephine L. Feliciano, MD, discusses established and emerging therapeutic developments for patients with non–small cell lung cancer with less common driver mutations.

FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC

September 12th 2018

The FDA has granted a priority review designation to single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression ≥1% and no EGFR or ALK genomic tumor aberrations.

Dr. Papadimitrakopoulou on Impactful Targeted Therapies in Lung Cancer

September 10th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses impactful targeted therapies in lung cancer.

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

September 8th 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Immunotherapy Inches Into SCLC Landscape

September 8th 2018

Josephine L. Feliciano, MD, discusses the role of immunotherapy and the potential of targeted agents in small cell lung cancer.

Dr. Brahmer on the IMpower150 Trial in NSCLC

September 7th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Dr. Levy on Investigational Biomarkers of Response to Immunotherapy in NSCLC

September 7th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

FDA Delays Decision on Frontline Atezolizumab for NSCLC

September 6th 2018

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

FDA Grants LOXO-292 Breakthrough Designation for NSCLC, MTC

September 5th 2018

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer or RET-mutant medullary thyroid cancer.

Dr. Langer on the Impact of the PACIFIC Trial on Stage III NSCLC

September 5th 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the PACIFIC trial results on the treatment landscape of stage III non–small cell lung cancer.

NSCLC Findings Support Upfront Immunotherapy

September 2nd 2018

In the setting of advanced non–small cell lung cancer, the choice of up-front immunotherapy or chemotherapy, or combinations of both, is aided by findings from several trials.

Dr. Naidoo on Treating Immune-Related Adverse Events in NSCLC

August 31st 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).